Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2011 Aug 14;17(30):3497-502. doi: 10.3748/wjg.v17.i30.3497.

Gemcitabine in elderly patients with advanced pancreatic cancer.

Author information

  • 1Pôle des Maladies de l'Appareil Digestif, Service de Pancréatologie, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92110 Clichy, France.

Abstract

AIM:

To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer.

METHODS:

All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC).

RESULTS:

Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer (metastatic: n = 20, locally advanced: n = 18) were studied. Among them, 30 (79%) were able to receive chemotherapy [median number: 9 infusions (1-45)]. Six patients (23%) had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients (11%) had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo).

CONCLUSION:

Tolerance and efficacy of gemcitabine-based chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.

KEYWORDS:

Cancer; Elderly; Gemcitabine; Pancreas

PMID:
21941416
[PubMed - indexed for MEDLINE]
PMCID:
PMC3163247
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk